ClinicalTrials.gov
public full text
Public Domain
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients#1095576
- Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation#872887
- Semaglutide 2.4 mg in Patients With Poor Weight-loss#807282
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.#864362
- Semaglutide's Weight Loss Effects in Obesity#1102405
Record · ID 898531
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive